By Nathan Allen 
 

Novartis AG's (NOVN.EB) Sandoz subsidiary said Friday it has presented positive data from two phase 3 studies of its Zessly and Erelzi biosimilars.

Results from the two studies show the drugs, which are used to treat rheumatoid arthritis, matched their reference medicine in terms of safety, efficacy and quality, Novartis said.

The research suggests that switching from the reference medicine to either of the biosimilars has no negative effects on safety or efficacy and doesn't damage the patient's ability to generate an immune response, Novartis said.

The European Union approved Zessly for use in Europe in May, while Erelzi received approval last June.

 

Write to Nathan Allen at nathan.allen@dowjones.com

 

(END) Dow Jones Newswires

June 15, 2018 01:57 ET (05:57 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Novartis Charts.